{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:42:09Z","timestamp":1772134929859,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["ID39087428"],"award-info":[{"award-number":["ID39087428"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["14-76103-184 CORNONA-11\/20"],"award-info":[{"award-number":["14-76103-184 CORNONA-11\/20"]}],"id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["1476103-184 CORONA-12\/20"],"award-info":[{"award-number":["1476103-184 CORONA-12\/20"]}],"id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells via surface-expressed angiotensin-converting enzyme 2 (ACE2). We used a surrogate virus neutralization test (sVNT) and SARS-CoV-2 S protein-pseudotyped vesicular stomatitis virus (VSV) vector-based neutralization assay (pVNT) to assess the degree to which serum antibodies from coronavirus disease 2019 (COVID-19) convalescent patients interfere with the binding of SARS-CoV-2 S to ACE2. Both tests revealed neutralizing anti-SARS-CoV-2 S antibodies in the sera of ~90% of mildly and 100% of severely affected COVID-19 convalescent patients. Importantly, sVNT and pVNT results correlated strongly with each other and to the levels of anti-SARS-CoV-2 S1 IgG and IgA antibodies. Moreover, levels of neutralizing antibodies correlated with the duration and severity of clinical symptoms but not with patient age. Compared to pVNT, sVNT is less sophisticated and does not require any biosafety labs. Since this assay is also much faster and cheaper, sVNT will not only be important for evaluating the prevalence of neutralizing antibodies in a population but also for identifying promising plasma donors for successful passive antibody therapy.<\/jats:p>","DOI":"10.1038\/s41423-020-00573-9","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T03:06:52Z","timestamp":1604286412000},"page":"936-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-7488","authenticated-orcid":false,"given":"Berislav","family":"Bo\u0161njak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia Catherina","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Willenzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Katrin","family":"Cordes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Puppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Ravens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian R.","family":"Schultze-Florey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"G\u00f6decke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Kleine-Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-7696","authenticated-orcid":false,"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Pink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg M. N.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Blasczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-5345","authenticated-orcid":false,"given":"Thomas F.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"573_CR1","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1002\/jmv.25884","volume":"92","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Clinical characteristics of 3062 COVID-19 patients: a meta-analysis. J. Med. Virol. 92, 1902\u20131914 (2020).","journal-title":"J. Med. Virol."},{"key":"573_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/M20-3012","volume":"173","author":"DP Oran","year":"2020","unstructured":"Oran, D. P., Topol, E. J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann. Intern. Med. 173, 362\u2013367 (2020).","journal-title":"Ann. Intern. Med"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1161\/CIRCULATIONAHA.120.047549","volume":"142","author":"PP Liu","year":"2020","unstructured":"Liu, P. P., Blet, A., Smyth, D. & Li, H. The science underlying COVID-19: implications for the cardiovascular system. Circulation 142, 68\u201378 (2020).","journal-title":"Circulation"},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/his.14134","volume":"77","author":"T Menter","year":"2020","unstructured":"Menter, T. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 77, 198\u2013209 (2020).","journal-title":"Histopathology"},{"key":"573_CR7","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46, 846\u2013848 (2020).","journal-title":"Intensive Care Med."},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"573_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).","journal-title":"Nat. Commun."},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"Y Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429\u2013446.e14\u00a0(2020).","journal-title":"Cell"},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355\u2013362 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"102885","DOI":"10.1016\/j.ebiom.2020.102885","volume":"57","author":"I Odak","year":"2020","unstructured":"Odak, I. et al. Reappearance of effector T cells is associated with recovery from COVID-19. EBioMedicine 57, 102885 (2020).","journal-title":"EBioMedicine"},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 17, 533\u2013535 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","volume":"26","author":"I Thevarajan","year":"2020","unstructured":"Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. 26, 453\u2013455 (2020).","journal-title":"Nat. Med."},{"key":"573_CR15","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 2020; 2020.04.17.20061440."},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"52","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity 52, 971\u2013977.e3 (2020).","journal-title":"Immunity"},{"key":"573_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","journal-title":"Cell"},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/infdis\/jiaa229","volume":"222","author":"G Zhang","year":"2020","unstructured":"Zhang, G., Nie, S., Zhang, Z. & Zhang, Z. Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019. J. Infect. Dis. 222, 183\u2013188 (2020).","journal-title":"J. Infect. Dis."},{"key":"573_CR19","doi-asserted-by":"publisher","unstructured":"Lou, B. et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur. Respir. J. 2020. https:\/\/doi.org\/10.1183\/13993003.00763-2020.","DOI":"10.1183\/13993003.00763-2020"},{"key":"573_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2020.05.020","volume":"146","author":"MK \u00d6z\u00e7\u00fcr\u00fcmez","year":"2020","unstructured":"\u00d6z\u00e7\u00fcr\u00fcmez, M. K. et al. SARS-CoV-2 antibody testing-questions to be asked. J. Allergy Clin. Immunol. 146, 35\u201343 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"573_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0140-6736(20)30788-1","volume":"395","author":"A Petherick","year":"2020","unstructured":"Petherick, A. Developing antibody tests for SARS-CoV-2. Lancet 395, 1101\u20131102 (2020).","journal-title":"Lancet"},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall, A. & Pirofski, L. The convalescent sera option for containing COVID-19. J. Clin. Investig. 130, 1545\u20131548 (2020).","journal-title":"J. Clin. Investig."},{"key":"573_CR23","doi-asserted-by":"publisher","first-page":"m1256","DOI":"10.1136\/bmj.m1256","volume":"368","author":"JH Tanne","year":"2020","unstructured":"Tanne, J. H. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ\u00a0368, m1256 (2020).","journal-title":"BMJ"},{"key":"573_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cmi.2020.08.005","volume":"26","author":"DJ Wooding","year":"2020","unstructured":"Wooding, D. J. & Bach, H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin. Microbiol. Infect. 26, 1436\u20131446 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"573_CR25","doi-asserted-by":"crossref","unstructured":"Lassauni\u00e8re, R. et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv 2020; https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.09.20056325v1.","DOI":"10.1101\/2020.04.09.20056325"},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3201\/eid2206.160010","volume":"22","author":"AN Alshukairi","year":"2016","unstructured":"Alshukairi, A. N. et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg. Infect. Dis. 22, 1113\u20131115 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"573_CR27","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.4049\/jimmunol.0903490","volume":"186","author":"F Tang","year":"2011","unstructured":"Tang, F. et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J. Immunol. 186, 7264\u20137268 (2011).","journal-title":"J. Immunol."},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1086\/500469","volume":"193","author":"W Liu","year":"2006","unstructured":"Liu, W. et al. Two\u2010year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J. Infect. Dis. 193, 792\u2013795 (2006).","journal-title":"J. Infect. Dis."},{"key":"573_CR29","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3201\/eid1310.070576","volume":"13","author":"LP Wu","year":"2007","unstructured":"Wu, L. P. et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg. Infect. Dis. 13, 1562\u20131564 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"C Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol"},{"key":"573_CR31","doi-asserted-by":"publisher","first-page":"e0189073","DOI":"10.1371\/journal.pone.0189073","volume":"12","author":"C Brinkmann","year":"2017","unstructured":"Brinkmann, C. et al. The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells. PLoS One 12, e0189073 (2017).","journal-title":"PLoS One"},{"key":"573_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","volume":"78","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M., Kleine-Weber, H. & P\u00f6hlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779\u2013784.e5 (2020).","journal-title":"Mol. Cell"},{"key":"573_CR33","doi-asserted-by":"publisher","first-page":"e25858","DOI":"10.1371\/journal.pone.0025858","volume":"6","author":"M Berger Rentsch","year":"2011","unstructured":"Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS One 6, e25858 (2011).","journal-title":"PLoS One"},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1099\/vir.0.80788-0","volume":"86","author":"A Hanika","year":"2005","unstructured":"Hanika, A. et al. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol. 86, 1455\u20131465 (2005).","journal-title":"J. Gen. Virol."},{"key":"573_CR35","first-page":"21","volume":"2","author":"E Procko","year":"2020","unstructured":"Procko, E. The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. bioRxiv Prepr. Serv. Biol. 2, 21\u201324 (2020).","journal-title":"bioRxiv Prepr. Serv. Biol."},{"key":"573_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","volume":"17","author":"C Yi","year":"2020","unstructured":"Yi, C. et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell. Mol. Immunol. 17, 621\u2013630 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"573_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"573_CR38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"Q-X Long","year":"2020","unstructured":"Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med"},{"key":"573_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","volume":"41","author":"S Jiang","year":"2020","unstructured":"Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355\u2013359 (2020).","journal-title":"Trends Immunol."},{"key":"573_CR40","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI138745","volume":"130","author":"EM Bloch","year":"2020","unstructured":"Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Investig. 130, 2757\u20132765 (2020).","journal-title":"J. Clin. Investig."},{"key":"573_CR41","doi-asserted-by":"publisher","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","volume":"5","author":"L Premkumar","year":"2020","unstructured":"Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020).","journal-title":"Sci. Immunol"},{"key":"573_CR42","doi-asserted-by":"publisher","unstructured":"Wu, F. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. SSRN Electron. J. 2020. https:\/\/doi.org\/10.2139\/ssrn.3566211.","DOI":"10.2139\/ssrn.3566211"},{"key":"573_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 1\u20136 (2020).","journal-title":"Nat. Commun."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-00573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-00573-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-00573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:22:54Z","timestamp":1684603374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-00573-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-00573-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.12.20151407","asserted-by":"object"}]},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}